Fate Therapeutics makes two appointments, one promotion
This article was originally published in Scrip
Fate Therapeutics, a biopharmaceutical company developing cellular therapeutics for the treatment of life-threatening diseases, has named Dr Wendy Levin vice-president of clinical development and Walter Grubb vice-president of business development. Dr Levin, a board-certified hematologist/oncologist, joins Fate from MEI Pharma, where she was vice-president of clinical development and medical affairs. Mr Grubb was previously executive director of business development and commercial operations at Ambit Biosciences.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.